MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

renal protection

  • Home
  • renal protection
Ilofotase Alfa in Preventing Acute Kidney Injury Post-Cardiac Surgery: Insights from a Phase 2 Randomized Trial
Posted inCardiology Nephrology news

Ilofotase Alfa in Preventing Acute Kidney Injury Post-Cardiac Surgery: Insights from a Phase 2 Randomized Trial

Posted by By MedXY 09/24/2026
A phase 2 randomized trial found that ilofotase alfa did not significantly reduce kidney injury or improve outcomes in high-risk patients undergoing on-pump cardiac surgery, though it was safe and well tolerated.
Read More
Flexovital Food Supplement Shows Promise in Mitigating Cardiovascular-Kidney-Metabolic Syndrome in Preclinical Model
Posted inCardiology Diabetes & Endocrinology Nephrology Specialties

Flexovital Food Supplement Shows Promise in Mitigating Cardiovascular-Kidney-Metabolic Syndrome in Preclinical Model

Posted by By MedXY 08/30/2025
Flexovital, a nitric oxide-enhancing supplement, effectively attenuates metabolic, cardiovascular, and renal dysfunctions in a mouse model of cardiovascular-kidney-metabolic syndrome induced by unilateral nephrectomy and Western diet.
Read More
  • DOACs versus Warfarin for Cerebral Venous Thrombosis: Noninferiority Confirmed in Large-Scale Chinese Registry Study
  • Focal Congenital Hyperinsulinism: Insights Into Spontaneous Glycemic Improvement Before Surgical Intervention
  • Return to Competition and Career Sustainability After Primary ACL Reconstruction in Football: Insights from Nationwide and Long-Term Studies
  • Predicting Walking Ability in Nontraumatic Spinal Cord Injury Using Machine Learning: A Novel Temporal Validation Study
  • Decoding Fluoride Discourse on X During the 2024 US Presidential Election: Implications for Public Health Communication
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top